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Women with established preeclampsia (PE) have increased plasma concentration of
free fetal hemoglobin. We measured two hemoglobin scavenger system proteins,
hemopexin (Hpx) and alpha-1-microglobulin (A1M) in maternal plasma using enzyme-
linked immunosorbent assay during the late second trimester of pregnancy in women
with high and low risk of developing PE. In total 142 women were included in nested
case-control study: 42 women diagnosed with PE and 100 controls (49 randomly
selected high-risk and 51 low-risk controls). The concentration of plasma A1M in
high-risk controls was higher compared to low-risk controls. Women with severe
PE had higher plasma A1M levels compared to women with non-severe PE. In
conclusion, the concentration of plasma A1M is increased in the late second trimester
in high-risk controls, suggesting activation of endogenous protective system against
oxidative stress.
Keywords: preeclampsia, heme, hemopexin, alpha-1 microglobulin, aspirin
INTRODUCTION
Preeclampsia (PE) is a relatively common hypertensive disorder in pregnancy, affecting 4,6% of
pregnancies worldwide (Abalos et al., 2013). The specific etiology of PE is, however, still not
completely described. According to the most well-accepted model, PE is a two-stage disorder
(Redman, 1991; Redman et al., 2014). The abnormal modification of the spiral arteries during
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placental development is thought to be the initial stage leading to
reduced utero-placental perfusion and increased oxidative stress
that in turn causes placental damage. Circulating toxic factors
derived from the placenta cross the blood-placenta barrier and
leak into the maternal circulation where they in turn trigger
an inflammatory response and general endothelial damage.
As a consequence of that, general organ damage develops,
which leads to the typical manifestations of PE after 20th week
of gestation, including hypertension, edema and proteinuria.
Circulating syncytiotrophoblast microvesicles (Smarason et al.,
1996), free fetal DNA (Zhong et al., 2002), cytokines (Hamai
et al., 1997) and antiangiogenic factors (Powe et al., 2011) have
been postulated as endothelial toxic factors derived from the
fetus and the placenta. However, we still lack a full explanation
on how placental damage leads to distinct maternal and fetal
manifestations that occur either during early pregnancy or late
pregnancy, so called early onset PE and late-onset PE. Early onset
PE is linked to poor placentation while the late-onset is more
determined by maternal risk factors such as obesity, diabetes
mellitus and chronic hypertension, which are associated with a
higher pre-pregnancy level of vascular inflammation (Roberts
and Redman, 1993; Ness and Roberts, 1996).
Extracellular fetal hemoglobin (HbF) has been introduced in
a series of earlier studies and suggested to have a crucial role in
the etiology of PE (Hansson et al., 2013). Increased synthesis of
HbF in the placenta was indicated by an up-regulation of the HbF
genes and there was an accumulation of extracellular HbF in the
vascular lumen of PE placenta (Centlow et al., 2008). Extracellular
HbF induces oxidative stress by formation of reactive oxygen
species resulting in damage to the blood-placenta barrier and
leakage of extracellular HbF into the maternal circulation
(May et al., 2011). As a consequence, plasma concentration of
extracellular HbF has been shown to be increased in maternal
plasma as early as the first trimester in women who later develop
PE (Anderson et al., 2011). Increased plasma levels in the late
third trimester has been shown to correlate to the maternal blood
pressure (Anderson et al., 2018).
There are several defense mechanisms which protect
against the harmful effects of extracellular hemoglobin (Hb).
Haptoglobin (Hp) is the most important protective scavenger
protein that binds extracellular Hb in plasma resulting in
a complex that in turn is cleared via CD163 receptors on
macrophages (Kristiansen et al., 2001; Schaer et al., 2006).
Hemopexin (Hpx) has a complementary role to bind extracellular
heme that is released as a metabolite when Hb is degraded by
the rate-limiting enzyme heme-oxygenase (HO-1) (Nielsen
et al., 2010; Tolosano et al., 2010). The resulting complex
is cleared from the circulation by liver parenchymal cells
via receptor-mediated endocytosis involving CD91/LRP1.
Alpha-1-microglobulin (A1M) is another component of the
heme scavenger system (Akerstrom and Gram, 2014). It is a
lipocalin with heme-binding properties as well as being an
antioxidant due to radical-scavenging and reductase properties.
In a series of studies (Gram et al., 2015; Anderson et al., 2018),
it has been shown that the plasma levels of Hp and Hpx are
reduced, suggesting that in cases where the maternal endogenous
protection system against extracellular HbF is overwhelmed,
PE becomes clinically manifest. Cellular A1M expression of
A1M is upregulated by increased oxidative stress and Hb/heme
exposure (Olsson et al., 2007) and previous investigations have
shown increased circulating plasma levels of A1M in women
pregnant with PE (Olsson et al., 2010; Anderson et al., 2011)
consistent with high circulating levels of Hb, heme and oxidants
in this disease.
In the present study, we analyzed the plasma levels of A1M
and Hpx in order to further understand the dynamics of these
components of the Hb/heme scavenger system in the second
trimester in women with high and low risk of developing PE. The
cohort of patients were stratified according to known maternal
risk factors, intervention with acetylsalicylic acid (ASA) as well as
neonatal outcome.
MATERIALS AND METHODS
Study Population
The present nested case-control study is a part of the
multidisciplinary “Prediction and Prevention of Pre-eclampsia
and Intrauterine Growth Restriction” (PREDO) project.
Women with known risk factors for PE were prospectively
recruited between September 2005 and June 2009 at ten
participating maternity clinics in Finland. The ethics Committee
at the Helsinki and Uusimaa Hospital District approved
the study and written informed consent was obtained from
all participants.
In total 142 women were included in this study: 42 women
diagnosed with PE and 100 controls (49 randomly selected high-
risk and 51 low-risk controls). Seven women with PE participated
in the ASA trial (part of the PREDO project), as well, and were
treated with low dose acetylsalicylic acid (mini-ASA 100mg/d)
starting before 14th week of gestation. Three women who were
taking mini-ASA and did not develop PE, were included as
controls for this sub-group. The inclusion and exclusion criteria
are described in Supplementary Table S1.
Preeclampsia was defined as a systolic blood pressure
≥140 mmHg and/or a diastolic blood pressure ≥90 mmHg
occurring after 20th weeks of gestation combined with a urinary
24-h protein excretion of ≥0.3 g or the dipstick equivalent in
two consecutive measurements. Severe PE was defined as systolic
blood pressure ≥160 mmHg and/or diastolic blood pressure
≥110 mmHg and/or proteinuria ≥5 g/24 h. Small for gestational
age (SGA) was defined as a birthweight ≤minus 2 SDs.
All participants had their first visit at 12+0–14+0 weeks
of gestation. Uterine artery blood flow was measured with
Doppler ultrasound examination. Gestational age was confir-
med by crown-rump length measurement. The first tri-
mester mean arterial pressure (MAP) was calculated with the
equation: MAP = diastolic blood pressure + (systolic blood
pressure – diastolic blood pressure)/3.
Fasting blood samples were collected in all three trimesters.
Plasma was separated within an hour by centrifugation and
stored in −80◦C until analysis. In the present study we
determined serum A1M and Hpx concentrations from samples
drawn at 26+0 to 28+0 weeks of gestation.
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Hemopexin ELISA
The Hpx concentrations were measured with a Human
Hemopexin ELISA Kit from Genway Biotech Inc. The analysis
was performed according to manufacturer’s instructions and
the absorbance was read at 450 nm using a Wallac 1420
Multilabel Counter.
A1M ELISA
The A1M concentrations were measured with an in-house A1M
ELISA. Flat-bottom ninety six-well microtiter plates were coated
with mouse monoclonal anti-A1M antibodies (clone 35.14) by
incubation overnight at+4◦C under sealing film with 100µl/well
of a 5 µg/ml-solution in PBS. After washing three times with
PBS + 0.05% tween-20, 100 µl of human urinary A1M reference
standard samples (1.56 – 100 ng/ml in PBS + 0.05% tween-20)
or unknown plasma samples (diluted 1000× with PBS + 0.05%
tween-20) were added to the wells and incubated under sealing
film for 1 h at room temperature, darkness and rotational shaking
250–500 rpm. After washing three times with PBS + 0.05%
tween-20, 100 µl/well of the detection antibody solution was
added (horse radish peroxidase-coupled mouse monoclonal anti-
A1M antibody clone 57.10; 5 ng/ml in PBS + 0.05% tween-20)
and incubated under sealing film for 1 h at room temperature,
darkness and rotational shaking 250–300 rpm. After washing
three times with PBS + 0.05% tween-20, 100 µl/well of TMB
substrate (SureBlueTM TMB Microwell Peroxidase Substrate,
KPL cat. no. 50-00-04) was added, sealed, and incubated 20 min
without shaking, and the reaction was stopped by adding
100 µl/well of 1 M sulfuric acid. Absorbance at 450 nm was
read in a Wallac 1420 Multilabel Counter (Perkin Elmer Life
Sciences). The monoclonal anti-A1M antibodies were prepared
against human urinary A1M by Agrisera AB (Vännäs, Sweden).
Human urinary A1M was prepared in our lab as described
(Akerstrom et al., 1995).
Statistical Analysis
Statistical analyses were performed using SPSS version 25.0
statistic software package. Normally distributed data were
analyzed using one-way ANOVA followed by Tukey’s post hoc
tests. Kruskal-Wallis and Mann-Whitney test were used in
case the data were not normally distributed and Bonferroni
corrections were used in post hoc comparisons. Statistical
significance was defined as p< 0.05.
RESULTS
Patient demographics and clinical characteristics are shown in
Table 1, 2. Women affected by PE had higher body mass index
(29,3 kg/m2) compared to controls (23,7 kg/m2). There were less
primiparas among women affected by PE compared to controls.
There were less women with a previous pregnancy complicated
by PE among controls compared to women affected by PE.
The distributions of plasma Hpx and A1M across the
groups are shown in Figures 1A,B. Pairwise comparisons using
significance values adjusted by the Bonferroni correction for
multiple tests revealed that the concentration of Hpx in women
TABLE 1 | Demographics of patients and controls.
Women not Women
affected by affected by
PE (n = 100) PE (n = 42) P-value ORa 95% CI
Lower Upper
Age, years (SD)b 31.3 (4.4) 31.6 (5.2) 0.74 1.01 0.94 1.10
BMI,
pre-pregnancy,
kg/m2 (IQR)c
23.7 (7.3) 29.3 (10.6) <0.01 1.09 1.03 1.15
Primiparous, n
(%)
42 (42.0) 10 (23.8) 0.04 1.53 1.01 2.30
Infertility
treatment, n (%)
11 (11.0) 5 (11.9) 0.77 1.19 0.38 3.70
Chronic disease,
n (%)
37 (37.0) 22 (52.4) 0.67 0.18 0.80 3.26
Education, n (%)
Elementary or
lessd
0 (0.0) 3 (7.9) 0.02
High school or
vocational school
22 (22.0) 8 (19.0) 0.64 0.90 0.36 2.26
Intermediate 32 (32.0) 19 (45.2) 0.83 0.90 0.36 2.26
University 40 (40.0) 7 (17.0) 0.01 0.32 0.13 0.79
Prior
preeclampsia
14 (14.0) 21 (50.0) <0.01 0.16 0.07 0.37
SGA in previous
pregnancy
9 (9.0) 4 (9.5) 0.92 0.94 0.27 3.24
Chronic
hypertension
14 (14.0) 10 (23.8) 0.16 0.52 0.21 1.29
Prior GDM 4 (4.0) 4 (9.5) 0.32 0.50 0.13 1.96
BMI ≥ 30 kg/m2 22 (22.0) 16 (38.1) 0.05 0.46 0.21 1.00
Prior fetus
mortuusd
2 (2.0) 1 (2.4) 1.00
abinary logistic regression, bmean, cmedian, dfisher’s exact test; PE = preeclam-
psia, OR = odds ratio, CI = confidence interval, SD = standard deviation,
BMI = body mass index. There was one type I diabetes mellitus and one Sjögren’s
syndrome in women who did not develop preeclampsia. There was not systemic
lupus erythematosus in either group.
with PE was higher compared to low-risk normotensive women
(median concentration 1.21 mg/ml versus 1.04 mg/ml, p = 0.014).
There was no significant difference in Hpx concentration between
women with PE and high-risk normotensive women (median
concentration 1.11 mg/ml) or between high-risk and low-risk
normotensive women. The concentration of A1M in high-risk
controls was higher compared to low-risk controls (median
concentration 16.08µg/ml vs. 13.09µg/ml, p = 0.002). There was
no significant difference in A1M concentration between women
with PE and high-risk controls or between women with PE and
low-risk controls.
The concentrations of plasma Hpx and A1M in women with
PE are shown in Table 3. We found no difference in Hpx or A1M
concentrations between women with PE who gave birth to SGA
infant and women with PE who gave birth to non-SGA infant.
The concentration of A1M in women with severe PE was higher
compared to women with non-severe PE. The distributions of
Hpx and A1M across the subgroups of PE, high- and low-risk
controls are shown in Figures 1C,D.
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TABLE 2 | Clinical characteristics of patients and controls.
Women not Women
affected by affected by 95% CI
PE n = 100 PE n = 42 P-value OR Upper Lower
Weight change
during pregnancy,
kg/m2
14.5 (7.8) 12.0 (6.6) 0.18 0.95 0.88 1.02
Gestational
diabetes, n (%)
17 (17.0) 12 (28.6) 0.12 0.51 0.22 1.20
I trimester mean
arterial pressure,
mmHg
89.7 (15.7) 98.8 (13.8) <0.01 1.07 1.04 1.11
I trimester mean
uterine artery PI
0.99 (0.35) 1.25 (0.47) <0.01 14.64 3.45 62.04
Highest mean
arterial pressure,
mmHg
100.0 (13.5) 128.5 (15.2) <0.01 1.16 1.11 1.22
Gestational weeks
at birth
40.3 (1.9) 38.4 (3.2) <0.01 0.53 0.41 0.70
Apgar score at
5 min
9 (1) 9 (2) 0.32 0.80 0.51 1.25
Umbilical artery pH 7.25 (0.13) 7.25 (0.13) 0.24 0.08 <0.01 5.57
Newborn
birthweight, g
3590 (651) 3109 (1259) <0.01 0.999 0.998 0.999
Placental weight, g 605 (175) 540 (173) <0.01 0.995 0.992 0.998
Continuous variables are presented as median values with interquartile range in
parenthesis. n=number of cases, PE=preeclampsia.
Seven PE women received mini-ASA during the pregnancy
and one of them gave birth to SGA infant. Thirty-five PE
women did not receive mini-ASA and eight of them gave birth
to SGA infant. Women who received ASA had higher Hpx
concentration compared to women who did not receive ASA
(median concentration 1,28 mg/ml versus 1,09 mg/ml, p = 0,025).
DISCUSSION
To the best of our knowledge, this is the first study evaluating
the levels of maternal plasma Hpx and A1M in the late second
trimester in PE women as well as in high- and low-risk controls
without PE. The strength of the study is a carefully characterized
cohort, where both women with predetermined risk factors for
PE and a low-risk reference group were prospectively recruited
(Girchenko et al., 2017).
Our analysis shows a significantly higher plasma A1M
concentration in high-risk controls compared to low-
risk controls, while there was no significant difference in
concentration of A1M between PE women and controls. In
previous studies (Olsson et al., 2010; Anderson et al., 2011, 2016;
Gram et al., 2015), the concentration of A1M in PE women was
increased compared to controls when it was analyzed during
the first trimester and third trimester, 24 h prior to delivery.
In the aforementioned studies, normotensive pregnant women
had been studied as a single undivided group, irrespective of
risk factors for PE. However, it is reasonable to hypothesize that
high-risk women are a distinct group characterized by increased
oxidative stress compared to low-risk women.
In the present cohort, pre-pregnancy obesity was among the
criteria conferring high-risk status to normotensive pregnant
women. Obesity is associated with systemic oxidative stress
(Furukawa et al., 2004). It can therefore be assumed that in
high-risk controls, the endogenous protection system against
oxidative stress is activated. The housekeeping protein A1M is
an extravascular scavenger and tissue repair protein which has
an important role in cleaning oxidative radicals and heme. It is
upregulated during oxidative stress in general and by hemolysis
specifically (Akerstrom and Gram, 2014). Thus, our results may
suggest that increased oxidative stress is present in high-risk
normotensive pregnant women compared to low-risk controls
in late second trimester. A serious weakness with this argument,
however, is that we have not included evaluation of oxidative
stress markers. Evaluation of oxidative stress markers and
reactive oxidative species measurements need to be undertaken
before the association between A1M and oxidative stress in
high-risk normotensive women is more clearly understood.
Although A1M has not been shown to be an acute-phase protein,
increased levels of A1M in high-risk normotensive women as
a result of chronic inflammation related to obesity might be
another explanation and needs to be clarified in further studies
(Akerstrom and Gram, 2014).
Interestingly, the median plasma A1M concentration in
high-risk normotensive women was increased compared to PE
women, although the difference was not statistically significant.
Higher concentration of A1M may confer its protective
effect ameliorating the clinical impact of oxidative stress and
preventing the development of PE in high-risk controls who
remain asymptomatic. In line with this assumption, intravenous
administration of a recombinant version of A1M in PE animal
models has been successful in eliminating or at least significantly
reducing the manifestations of preeclampsia (Sverrisson et al.,
2014; Nääv et al., 2015; Gunnarsson et al., 2017). One can
therefore speculate that the administration of exogenous A1M
might have a similar effect in humans and PE women also.
Recent evidence suggests that extracellular HbF is elevated
in the fetal circulation of pregnancies complicated by fetal
growth restriction (Brook et al., 2018). We expect that among
SGA infants in our cohort there are both constitutionally small
infants and infants that have not reached their growth potential
because of placental dysfunction. In the latter case, we expect that
extracellular HbF in the fetal circulation is elevated causing, as
we have previously shown (Centlow et al., 2008; May et al., 2011),
damage to blood-placenta barrier and consequently leaking into
maternal circulation, depleting Hpx. We hypothesized thus that
women with PE and SGA infant would have lower levels of Hpx
compared to women with PE and non-SGA infant, because Hpx
binds and detoxifies heme and HbF that is released from the
feto-placental unit. Although the levels of plasma Hpx was lower
in women with PE who gave birth to SGA infant compared to
women with PE and non-SGA infant, the difference was not
significant. Type II error is possible due to a small sample size.
One woman in the group of women with PE who gave birth to
SGA infant had exceptionally high plasma Hpx and A1M values
and this increased variability substantially. This woman differed
from the other in that group by having a medical history of
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FIGURE 1 | (A): Distribution of hemopexin across groups. (B): Distribution of A1M across groups. (C): Distribution of hemopexin across subgroups of PE, high- and
low-risk controls. (D): Distribution of A1M across subgroups of PE, high- and low-risk controls.
TABLE 3 | Values of A1M and hemopexin across subgroups of women with PE.
Hemopexin (mg/ml) A1M (µg/ml)
PE onset late onset (n = 31) versus early onset (n = 11) 1.22 (0.32) versus 1.16 (0.64), p = 0.66 13.34 (3.26) versus 16.66 (3.96), p = 0.07
SGA no (n = 34) versus yes (n = 8) 1.22 (0.41) versus 0.97 (0.52), p = 0.183 13.20 (3.84) versus 16.85 (5.83), p = 0.11
PE severity mild (n = 21) versus severe (n = 21) 1.22 (0.56) versus 1.21 (0.44), p = 0.84 12.30 (4.46) versus 14.83 (5.23), p = 0.04
ASA no (n = 35) versus yes (n = 7) 1.20 (0.43) versus 1.31 (0.51), p = 0.16 14.24 (4.42) versus 12.13 (3.10), p = 0.30
Continuous variables are presented as median values with interquartile range in parenthesis. n=number of cases.
chronic hypertension and thus superimposed PE and she was the
only woman who received mini-ASA in the group of women with
PE who gave birth to SGA infant.
Recent studies (Ferrazzi et al., 2018; Tay et al., 2018)
suggest that women with PE and SGA or growth restricted
fetus have a distinct cardiovascular phenotype characterized by
lower cardiac output and higher peripheral vascular resistance.
It is tempting to speculate that there is a connection between
the impaired cardiovascular function and the decreased levels
of heme scavenger Hpx. A possible explanation may be
leakage of extracellular HbF of fetoplacental origin in maternal
circulation. As a consequence, heme is released from metabolized
extracellular HbF and depleting Hpx as recently shown
(Anderson et al., 2018). Imbalance in the scavenging capacity
causes vasoconstriction by reducing nitric oxide availability and
impaired cardiac function. In fact, heme has been shown to
induce contractile dysfunction in human cardiomyocytes in vitro
(Alvarado et al., 2015). Furthermore, Hpx has been shown to
have cardio-protective effect and it preserves systolic function
by limiting heme-driven oxidative stress in mice (Ingoglia et al.,
2017). Further studies, where cardiac function is evaluated
simultaneously with the concentration of heme in maternal
circulation, are needed to further clarify whether this suggested
mechanism has clinical relevance.
In contrast to previous studies, we found increased plasma
concentration of Hpx in PE women compared to low-risk
controls. After excluding controls and PE women treated with
mini-ASA, there was no statistically significant difference in
the concentrations of Hpx between PE women and controls.
In previous studies, where women treated with mini-ASA were
not included, the concentration of Hpx was decreased, albeit
marginally, in early pregnancy in women who later developed PE
(Anderson et al., 2016). The concentration of Hpx in PE women
has been shown to be even more decreased compared to controls
just before delivery (Anderson et al., 2018). Thus, when focusing
on women not treated with mini-ASA, our results suggest that
Hpx depletion, due to heme-Hpx binding, is a continuous
process, which starts slowly in early pregnancy and intensifies in
third trimester when PE is manifested clinically. Further studies
with a significantly larger patient group are needed if we try
to detect the very marginal differences of the early stages of
this process in order to clarify the dynamics of this process.
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As regards to mini-ASA prophylaxis, 3 high-risk controls
and 7 PE women who had participated in ASA trial were
included in this study. Overall, these 10 women had significantly
higher plasma Hpx concentration compared to controls and
PE women who did not receive mini-ASA prophylaxis. Mini-
ASA could possibly have an impact on Hpx concentration by
improving placental perfusion. We have previously hypothesized
that the up-regulation of HbF gene expression in the preeclamptic
placenta may be induced by hypoxia caused by insufficient
placental perfusion (Gram et al., 2015). Mini-ASA may improve
the placental perfusion through inhibition of the potent
vasoconstrictor Thromboxane A2 (TXA2) or by preventing
placental thrombosis formation improving the blood flow in
the PE placenta. Improved placental perfusion could then
possibly prevent up-regulation of the HbF gene expression
thereby reducing the leakage of HbF and heme into the
maternal circulation. As previously shown, small amount of heme
administered intravenously in rhesus monkeys increases the Hpx
levels by increasing the rate of Hpx synthesis (Foidart et al., 1982).
In contrast, large amount of heme has been shown to reduces Hpx
levels by increased Hpx catabolism. Further studies are needed to
understand the role of mini-ASA on Hpx dynamics.
CONCLUSION
This study shows increased concentration of plasma
A1M in high-risk normotensive pregnant women in late
second trimester.
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